Psych CASC / OSCE · Psychopharmacology — renal and hepatic disease
Explaining psychotropic choices in CKD and cirrhosis (CASC)
CASC-style communication station: organ-aware lithium safety, NSAID counselling, benzodiazepine HE risk, and CAST-informed shared decision on antidepressants.
On this page & tools
Target exams
Station instructions (candidate)
You have 7 minutes. Explain in plain language why lithium needs kidney monitoring and why anti-inflammatory painkillers can raise lithium levels; why standard sleeping tablets (benzodiazepines) are risky with her liver disease; and how decisions about antidepressants in kidney disease are individualised — including that a major trial (CAST) found sertraline no better than placebo for depression symptoms in non-dialysis CKD, so expectations and non-drug options matter. Do not terrify her into stopping lithium without a plan. Do not promise cure. Check understanding and safety (suicide risk, who to call if confused or very unsteady).[1][2][3][5]
You have read the opening of this CASC / OSCE. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship atlas.
References6Show ledgerHide ledger
- [1]Hedayati SS, Gregg LP, Carmody T, et al. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial JAMA, 2017.PMID 29101402
- [2]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734
- [3]Grønbæk L, Watson H, Vilstrup H, et al. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites United European Gastroenterol J, 2018.PMID 29774154
- [4]McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis Lancet, 2012.PMID 22265699
- [5]Hedayati SS, Yalamanchili V, Finkelstein FO A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease Kidney Int, 2012.PMID 22012131
- [6]Telles-Correia D, Barbosa A, Cortez-Pinto H, et al. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity World J Gastrointest Pharmacol Ther, 2017.PMID 28217372